Company Overview of Laboratorios SALVAT, S.A.
Laboratorios SALVAT, S.A. manufactures pharmaceutical products for personal healthcare, digestive/metabolism, urology, ENT/ophthalmology, dermatology, and malaria. The company also engages in research projects in molecular diagnosis, regenerative medicine, and new forms of drug delivery. It offers its products in solid, semi-solid, and liquid pharmaceutical forms; specializes in blow-fill-seal contract manufacturing of small fill volume pharmaceutical unit dose sterile liquids, which include ear drops, eye drops, and other products. It markets its products through local licensees and distributors in Europe, America, Asia, Africa, and the Middle East. Laboratorios SALVAT, S.A. was founded in ...
C\ Gall, 30-36
Founded in 1955
Key Executives for Laboratorios SALVAT, S.A.
Medical Research Director
Compensation as of Fiscal Year 2016.
Laboratorios SALVAT, S.A. Key Developments
iCo Therapeutics Announces Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset
Nov 15 16
iCo Therapeutics announced a World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for a Novel Glaucoma Asset. Glaucoma candidate a novel and potentially first in class asset. Salvat to market glaucoma drug in EU with iCo receiving royalties. Exclusive option to acquire asset outright over multiple development stage milestones aggregate payments either $4.25 million or $4.5 million, based on option exercise timing. iCo obtains a worldwide exclusive option to glaucoma asset for a maximum of nine months iCo diligence activities during option period to focus on commercialization of asset. During option period minimal impact on corporate runway. SALVAT will continue to pay intellectual property costs during option period to date 29 patents have been issued.
Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) Otic Solution
Aug 29 16
Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC jointly announce the launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution, the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials. OTOVEL® is owned by SALVAT, and Arbor will be the exclusive distributor of the product in the U.S. OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (aged 6 months and older) due to S. aureus, S. pneumoniae, H. influenzae, M. catarrhalis, and P. aeruginosa. Two phase 3 multicenter, randomized, double-blind, active-controlled, parallel group trials were conducted to assess the efficacy and safety of OTOVEL® compared to ciprofloxacin otic solution and to fluocinolone acetonide otic solution.
Laboratorios Salvat Signs Distribution Agreement with Lee's Pharmaceutical (Hong Kong) and Taiwan
Jan 8 16
Laboratorios Salvat (Spain) and Lee's Pharmaceutical (Hong Kong) have signed a licence and supply agreement for the marketing and distribution of Duoxal (ciprofloxacin + fluocinolone acetonide) ear drops in mainland China, Hong Kong, Macau, and Taiwan, with an option to add Thailand, the companies said in a statement. Duoxal is indicated for the treatment of acute otitis media in patients with tympanostomy tubes, and acute otitis externa (swimmer's ear) in adults and children older than six months of age.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|